{"id":"cetirizine-tablets","safety":{"commonSideEffects":[{"rate":"7-12","effect":"Headache"},{"rate":"5-8","effect":"Somnolence"},{"rate":"3-5","effect":"Dry mouth"},{"rate":"2-4","effect":"Fatigue"},{"rate":"2-3","effect":"Pharyngitis"}]},"_chembl":{"chemblId":"CHEMBL1607273","moleculeType":"Small molecule","molecularWeight":"461.82"},"_dailymed":{"setId":"14a885e5-5e75-4a18-b5bc-6aaa748712db","title":"CETIRIZINE HYDROCHLORIDE (CETIRIZINE HYDROCHLORIDE TABLETS) TABLET, FILM COATED [PREFERRED PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetirizine competitively inhibits histamine at peripheral H1 receptors, preventing histamine-mediated allergic responses such as itching, urticaria, and rhinitis. As a second-generation antihistamine, it is highly selective for H1 receptors and has minimal central nervous system penetration due to its hydrophilic nature and low blood-brain barrier crossing, resulting in reduced sedation compared to first-generation antihistamines.","oneSentence":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on cells, reducing allergic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:56.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis (seasonal and perennial)"},{"name":"Chronic urticaria"},{"name":"Allergic conjunctivitis"}]},"trialDetails":[{"nctId":"NCT04568902","phase":"PHASE1","title":"Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-09-30","conditions":"Breast Neoplasms","enrollment":33},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":"Fabry's Disease","enrollment":8},{"nctId":"NCT06890260","phase":"NA","title":"The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife","status":"RECRUITING","sponsor":"Pengfei Qiu","startDate":"2025-04-11","conditions":"Allergic Rhinitis (Disorder), Electroacupuncture, Microneedle Knife","enrollment":90},{"nctId":"NCT04323566","phase":"PHASE2","title":"Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement","status":"ENROLLING_BY_INVITATION","sponsor":"Uppsala University Hospital","startDate":"2022-05-01","conditions":"Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia","enrollment":40},{"nctId":"NCT00751218","phase":"PHASE4","title":"A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-05-06","conditions":"Urticaria","enrollment":174},{"nctId":"NCT00751166","phase":"PHASE4","title":"A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Urticaria","enrollment":149},{"nctId":"NCT04071821","phase":"PHASE1","title":"Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg","status":"NOT_YET_RECRUITING","sponsor":"Seattle Gummy Company","startDate":"2025-05-01","conditions":"Allergy","enrollment":30},{"nctId":"NCT00650065","phase":"PHASE1","title":"Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT00649857","phase":"PHASE1","title":"Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT04175834","phase":"PHASE3","title":"Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2020-02-05","conditions":"Multiple Sclerosis, Infusion Reaction","enrollment":19},{"nctId":"NCT05476679","phase":"PHASE1, PHASE2","title":"Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events","status":"COMPLETED","sponsor":"Raziel Therapeutics Ltd.","startDate":"2022-09-25","conditions":"Submental Fat","enrollment":48},{"nctId":"NCT00794846","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":124},{"nctId":"NCT00794599","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":118},{"nctId":"NCT00794495","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":122},{"nctId":"NCT00780403","phase":"PHASE4","title":"Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Allergies","enrollment":220},{"nctId":"NCT00779116","phase":"PHASE4","title":"Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Allergies","enrollment":217},{"nctId":"NCT00974571","phase":"PHASE3","title":"Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-11","conditions":"Perennial Allergic Rhinitis","enrollment":1365},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT03772158","phase":"PHASE1","title":"Cetirizine Chewable Bioequivalence and Food Effect Study","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division","startDate":"2018-12-11","conditions":"Allergy","enrollment":40},{"nctId":"NCT04237090","phase":"PHASE3","title":"Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2020-02-14","conditions":"Breast Cancer, Lung Cancer, Ovarian Cancer","enrollment":27},{"nctId":"NCT03192488","phase":"PHASE4","title":"Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia","status":"COMPLETED","sponsor":"Indiana University","startDate":"2017-08-31","conditions":"Hypoxia, Altitude","enrollment":13},{"nctId":"NCT02543346","phase":"PHASE4","title":"Comparability and Standardization of Controlled Allergen Challenge Facilities","status":"COMPLETED","sponsor":"Queen's University","startDate":"2015-10","conditions":"Allergic Rhinitis","enrollment":98},{"nctId":"NCT01484119","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2011-12","conditions":"Seasonal Allergic Rhinitis","enrollment":630},{"nctId":"NCT00291642","phase":"PHASE2","title":"A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-01-01","conditions":"Rhinitis, Allergic, Seasonal","enrollment":551},{"nctId":"NCT01916226","phase":"PHASE4","title":"A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-01","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":682},{"nctId":"NCT01451996","phase":"PHASE4","title":"The Efficacy of Claritin in Healthy Subjects","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-10","conditions":"Healthy","enrollment":340},{"nctId":"NCT00972504","phase":"PHASE2","title":"723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-01","conditions":"Rhinitis, Allergic, Seasonal","enrollment":54},{"nctId":"NCT02613910","phase":"PHASE3","title":"Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2015-12-23","conditions":"Pemphigus","enrollment":1},{"nctId":"NCT00881127","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-07","conditions":"Allergies","enrollment":40},{"nctId":"NCT00881634","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-06","conditions":"Allergies","enrollment":40},{"nctId":"NCT00851344","phase":"PHASE2","title":"Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09","conditions":"Rhinitis, Allergic, Seasonal","enrollment":54},{"nctId":"NCT00150761","phase":"PHASE4","title":"Facial Thermography Study of Levocetirizine Versus Cetirizine","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-07","conditions":"Anti-allergic Agents","enrollment":60},{"nctId":"NCT01981499","phase":"PHASE1","title":"A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults","status":"TERMINATED","sponsor":"Pfizer","startDate":"2014-01","conditions":"Migraine","enrollment":31},{"nctId":"NCT01748344","phase":"PHASE2","title":"Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2012-11","conditions":"Seasonal Allergic Rhinitis","enrollment":58},{"nctId":"NCT00826943","phase":"PHASE4","title":"Is Levocetirizine Less Sedating Than Cetirizine?","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2009-01","conditions":"Allergic Rhinitis","enrollment":30},{"nctId":"NCT00544388","phase":"PHASE3","title":"Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-04","conditions":"Rhinitis, Allergic, Seasonal","enrollment":570},{"nctId":"NCT00561717","phase":"PHASE4","title":"A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-10","conditions":"Seasonal Allergic Rhinitis","enrollment":70},{"nctId":"NCT01127620","phase":"PHASE3","title":"Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2004-05","conditions":"Perennial Allergic Rhinitis","enrollment":650},{"nctId":"NCT01322282","phase":"PHASE1","title":"To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy","status":"COMPLETED","sponsor":"McNeil AB","startDate":"2011-02","conditions":"Allergy","enrollment":36},{"nctId":"NCT00420082","phase":"PHASE2","title":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2006-10","conditions":"Seasonal Allergic Rhinitis","enrollment":75},{"nctId":"NCT00504933","phase":"PHASE3","title":"Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2005-05","conditions":"Seasonal Allergic Rhinitis","enrollment":683},{"nctId":"NCT00375713","phase":"PHASE3","title":"Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-10","conditions":"Dermatitis, Eczema","enrollment":466},{"nctId":"NCT00240032","phase":"PHASE4","title":"A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-10","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT00863902","phase":"PHASE1","title":"A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-08","conditions":"Healthy","enrollment":26},{"nctId":"NCT00864279","phase":"PHASE1","title":"A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-08","conditions":"Healthy","enrollment":26},{"nctId":"NCT00776022","phase":"NA","title":"Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2005-04","conditions":"Healthy","enrollment":32},{"nctId":"NCT01064102","phase":"PHASE1","title":"Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2006-01","conditions":"Healthy","enrollment":30},{"nctId":"NCT01064115","phase":"PHASE1","title":"Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2006-01","conditions":"Healthy","enrollment":30},{"nctId":"NCT00639587","phase":"PHASE3","title":"Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-08","conditions":"Rhinitis, Allergic, Perennial","enrollment":149},{"nctId":"NCT00776139","phase":"NA","title":"Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2004-10","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cetirizine tablets","genericName":"Cetirizine tablets","companyName":"UCB Pharma","companyId":"ucb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on cells, reducing allergic symptoms. Used for Allergic rhinitis (seasonal and perennial), Chronic urticaria, Allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}